US biotech specialists move into cannabinoid fermentation

Interest continues to grow in the use of microbes to produce cannabinoids.
Intrexon, an American biotech company listed on the Nasdaq stock exchange, has announced a development in its microbial platform capable of producing cannabinoids for medical use.
It has created a yeast strain capable of producing low-cost, robust and consistent cannabinoid outputs through fermentation.
Exectuve directive Chris Savile said: “Microbial fermentation routes to produce cannabinoids provide advantages over traditional plant-based extraction. We expect to optimise strains to produce specific cannabinoids that may be commercialised in the coming years.”